News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EU Regulators Back AstraZeneca PLC (AZN) Thyroid Cancer Drug


11/18/2011 7:03:34 AM

European drug regulators have recommended AstraZeneca's new thyroid cancer pill Caprelsa, or vandetanib, for approval, giving a boost to a drug which has suffered past setbacks. The Anglo-Swedish drugmaker said in a statement on Friday its application for a marketing authorisation for Caprelsa received a positive opinion from the European Medicines Agency for the treatment of advanced and non-operable medullary thyroid cancer. Vandetanib was once seen as a potential $1 billion-plus blockbuster for AstraZeneca, but suffered a major setback after failing to extend survival in patients with lung cancer.

Read at Reuters
Read at Wall Street Journal
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES